EUCTR2004-000007-18-SE进行中（未招募）不适用
A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg Both Delivered Twice Daily via the DISKUS/ACCUHALER Inhaler on Lung Function and Dyspnoea in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Is male or female aged 40 - 80 years inclusive
- •2. Has an established clinical history of COPD stage II (As per the GOLD definition (GOLD 2003) which defines COPD as characterised by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases)
- •3. Provides a signed and dated written informed consent form prior to participation
- •4. Demonstrates a post-bronchodilator FEV1 of <80% and > 50% of predicted normal at Visit 1
- •5. Demonstrates a post-bronchodilator FEV1 / FVC ratio < 70% at Visit 1
- •6. Has poor reversibility of airflow obstruction defined as < 10% of the predicted normal FEV1 value recorded 30 minutes after inhalation of 400mcg VENTOLIN (FEV1 values of 10.1 to 10.4% will be rounded down to 10%; values of 10.5 to 10.9% will be rounded up to 11%). This must be demonstrated at Visit 1
- •7. Is a current or former smoker with a smoking history of > 10 pack-years (10 pack years is defined as 20 cigarettes (or equivalent if subject smoked cigars or a pipe) per day for 10 years, or 10 cigarettes per day for 20 years). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Smokers who have stopped smoking less than 6 months before Visit 1 will be defined as current smokers
- •8. Achieves a minimum score of ? 2 on the Modified Medical Research Council Dyspnoea Scale at Visit 1(See Appendix 3)
- •9. A female is eligible to enter this study if in addition to the above, she is of:
- •a) non-childbearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal), or
- •b) child-bearing potential but has a negative urinary pregnancy test at Visit 1 and agrees to take contraceptive precautions (including abstinence) which are adequate to prevent pregnancy during the study.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Is experiencing an exacerbation of COPD requiring treatment with oral corticosteroids and/or antibiotics or hospitilisation, or has experienced such exacerbation in the 4 weeks prior to Visit 1
- •2. Has a current medical diagnosis of asthma, eczema, atopic dermatitis and/or allergic rhinitis
- •3. Has a known respiratory disorder other than COPD (e.g. lung cancer, sarcoidosis, tuberculosis or lung fibrosis)
- •4. Has undergone lung surgery e.g., lung transplant and/or lung volume reduction
- •5. Had a chest X-ray indicating diagnosis other than COPD that might interfere with the study (chest X-ray to be taken at entry to the run-in period, if subject has not had one taken within the last 3 months)
- •6. Is a nursing mother
- •7. Requires regular (daily) or long term oxygen therapy (LTOT). LTOT is defined as ? 12 hours oxygen use per day with resting PO2 below 7.3
- •8. Is receiving ?-blockers (except eye drops)
- •9. Has serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study
- •10. Had any changes in COPD medication in the 4 weeks prior to Visit 1
- •11. Received antibiotic therapy and/or been hospitalised for a lower respiratory tract infection within the 4 weeks prior to Visit 1
- •12. Has received tiotropium bromide, inhaled corticosteroids or anti-leukotrienes including modulators of leukotriene production such as Zileuton, montelukast or zafirlukast within 14 days prior to Visit 1
- •13. Has received oral/parenteral corticosteroids within the 4 weeks prior to Visit 1
- •14. Has received any other investigational drugs within the 4 weeks prior to Visit 1
- •15. Has a known or suspected hypersensitivity to ß2-agonists, inhaled steroids or any components of the formulations (e.g. lactose or milk protein)
研究者
相似试验
进行中（未招募）
3 期
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' Buprenorphine transdermal system [BTDS]) And Placebo In Patients With Diabetic Peripheral Neuropathic Pain.ACTRN12609000647235Mundipharma Pty Limited186
进行中（未招募）
3 期
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' BTDS) And Placebo In Patients With Postherpetic Neuralgia.Post Herpetic NeuralgiaNeurological - Other neurological disordersACTRN12608000242325Mundipharma Pty Limited124
进行中（未招募）
不适用
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled,Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive DisorderMajor Depressive Disorder (MDD)EUCTR2004-004409-24-DEGlaxoSmithKline Research & Development364
进行中（未招募）
不适用
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability ofExtended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.Major Depressive Disorder (MDD)EUCTR2004-003803-19-SEGlaxoSmithKline Research & Development546
进行中（未招募）
1 期
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled,Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive DisorderEUCTR2004-004409-24-SKGlaxoSmithKline Research & Development